Stable sugar levels key to better outcomes

The findings shed new light on the importance of visit-to-visit variability for predicting future mortality and quality of life in diabetic patients.

Using patients from the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial of intensive glucose control and blood pressure lowering in type 2 diabetics, visit-to-visit variability (VVV) of HbA1c and glucose was evaluated from five measurements taken at visits three, six, 12 and 24 months after randomisation.

VVV was then compared with both macro and